Maricann to be exclusive cannabis supplier to established Canadian pharmacy chain Lovell Drugs

Toronto-based Maricann Group (CSE:MARI) (OTCQB:MRRCF) announced it has agreed with Lovell Drugs, Ontario’s oldest pharmacy chain, to be the exclusive provider of medical cannabis to its pharmacies.

The stock was up 5% to CAD$1.77 on midday trading. It has traded between $0.87 and $2.10 over the past year. The company has a market cap of $163.45m.

Lovell Drugs has already begun distribution of Maricann cannabis products to its patients, with the first prescription filled on December 1st, 2017. Maricann will fulfill prescriptions directly to Lovell Drugs’ patients through the existing Access to Cannabis for Medicinal Purposes Regulations (ACMPR).

Lovell Drugs and Maricann will together offer medical cannabis education for its pharmacists and allied community physicians. As an established pharmacy, Lovell Drugs is well positioned to educate and counsel patients on medical cannabis.

“We believe that our medical cannabis initiative to distribute cannabis directly to patients, with pharmacists as their primary source of counselling and information, is the better way,” said Ben Ward, CEO of Maricann. “Until pharmacists are permitted to distribute cannabis products to patients directly, as is the case with all other pharmaceuticals, …this distribution model will provide an effective interim solution.”

The agreement is for four years, with an option to extend another three years if the parties mutually agree. Lovell Drugs will receive a percentage of Maricann product sale revenue generated from patients serviced from Lovell Drugs’ retail pharmacies.

Source Maricann press release

Maricann to be exclusive cannabis supplier to established Canadian pharmacy chain Lovell Drugs

About Cannin Investment Group: Your Pot Stocks Experts

Cannin is your trusted resource for pot stocks. Our global team of experts evaluates all emerging pot stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best pot stock investments for 2020.

Use Cannin as your resource for:

Is it too late to invest in pot stocks? No! This is the perfect time to invest.

Market analysts expect the legal cannabis industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in pot stocks is now. Are you looking to buy stock in pot companies for 2020? Interested in emerging penny pot stocks? Looking for the best Canadian pot stocks to invest in? We can help.

Are you interested in pot stocks like Curaleaf, Trulieve, Aurora Cannabis, or Canopy Growth?

Predict price movements of pot stocks several hours in advance with our proprietary algorithmic stock trading software.

+25% Gains in 2020
+49.8% Gains in 2019
108% Backtested since 2012

We’re so confident you’ll love our algotrading pot stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.

Profit from the best pot stocks – we’ll show you how at cannin.com.

Marijuana Stocks, Pot Stocks, Algorithmic Stock Trading, Best Hemp Stocks to Buy

Maricann to be exclusive cannabis supplier to established Canadian pharmacy chain Lovell Drugs